Drug intelligence / Profile preview

VGX-2857

Development stage: Preclinical
Lead developer: Vogenx

Overview

VGX-2857 is an early-stage pharmaceutical candidate being developed by Vogenx for the indication of weight maintenance. As of early 2024, the drug is in the preclinical or early clinical stages of development. While Vogenx's lead program, mizagliflozin, is a first-in-class SGLT1 inhibitor targeting glucose and GIP secretion, the specific molecular target and modality of VGX-2857 have not yet been publicly disclosed by the company. The program is part of Vogenx's broader focus on metabolic diseases and post-bariatric care.

Beyond the preview

Go deeper on VGX-2857.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VGX-2857.

Explore the full profile